Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Metastatic Castrate Resistant Prostate Cancer (mCRPC) 2Severe Acute Respiratory Syndrome 1Prostatic Neoplasms 1Prostatic Hyperplasia 1Neoadjuvant Therapy \High Risk Prostate Cancer 1COVID-19 1Breast Neoplasms 1Alopecia 1

Interventions

Trastuzumab 625Paclitaxel 576Cyclophosphamide 555Docetaxel 484Capecitabine 401Letrozole 376Fulvestrant 326Doxorubicin 294Carboplatin 279Tamoxifen 275Anastrozole 243exemestane 228Radiotherapy 218Epirubicin 211Bevacizumab 196palbociclib 189pertuzumab 184Vinorelbine 167Lapatinib 167Gemcitabine 166pembrolizumab 162Surveys and Questionnaires 138Exercise 136Magnetic Resonance Spectroscopy 123Fluorouracil 119Blood Specimen Collection 118eribulin 117Albumin-Bound Paclitaxel 117Drug Therapy 111130-nm albumin-bound paclitaxel 111

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasms × proxalutamide × Clear all
NCT04103853 2021-09-24

Safety, Tolerability, and Pharmacokinetics of Proxalutamide Therapy in Women With Metastatic Breast Cancer

Suzhou Kintor Pharmaceutical Inc,

Phase 1 Completed
63 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡